Our website uses cookies to distinguish you from other users of our site. This helps us to continually improve your experience when using our website. We also use external analytics software which may set additional cookies to perform their analysis. These cookies (and any others in use) are detailed in our site Privacy and Cookie Policies. You can delete or disable these cookies in your web browser at any time but doing so may impact website functionality and user experience.

PhoreMost is a spin-out based on work by Professor Ashok Venkitaraman and Dr Grahame Mckenzie, both of the University’s MRC Cancer Unit.

This new model drug discovery company aims to develop drugs against targets previously thought to be ‘undruggable’, and to bring more effective, targeted medicines to patients. It was co-founded with PhoreMost CEO Dr Chris Torrance, a cancer researcher and entrepreneur. Cambridge Enterprise’s Life Sciences and Seed Funds teams worked with the Cambridge-based company, providing patent and licence support, as well as seed investment.

PhoreMost has developed a next-generation phenotypic screening platform called Site-Seeker to identify the best new targets for future therapies and how to drug them. Site-Seeker has the potential to significantly increase the diversity of novel therapeutics for cancer and other diseases where treatment options are severely limited.